Exelixis Announces Further Expansion to Clinical Research Protocol for Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Anti-PD-L1 Immunotherapy in Patients with Locally Advanced or Metastatic Solid Tumors

Exelixis (Nasdaq:EXEL) today announced an amendment to the protocol for COSMIC-021, the phase 1b trial of cabozantinib (CABOMETYX^®) in combination with atezolizumab (TECENTRIQ^®) in patients with locally advanced or metastatic solid tumors to add 10 new expansion cohorts to the trial. The primary objective in the expansion stage of this trial remains to determine the objective response rate in each cohort.

As quoted in the press release:

“We look forward to expanding this phase 1b COSMIC-021 clinical trial of cabozantinib in combination with atezolizumab in a number of additional tumor types, which include patient populations in significant need of new therapies that may improve response rates, slow disease progression and improve treatment outcomes,” said Gisela Schwab, M.D., President, Product Development and Medical Affairs and Chief Medical Officer, Exelixis. “We look forward to advancing this trial and to generating data that will inform late stage trials of cabozantinib in combination with immune checkpoint inhibitors.”

Click here to read the full press release.